Journal of Pain Research
June 1, 2022
Sandra J Drozdz, Akash Goel, Matthew W Mcgarr et al.
2 citations
Sandra J Drozdz,1 Akash Goel,1â 3 Matthew W McGarr,4 Joel Katz,3,5â 7 Paul Ritvo,5,7 Gabriella F Mattina,1 Venkat Bhat,8â 10 Calvin Diep,3 Karim S Ladha1,3,10 1Department of Anesthesia, St. Michaelâs Hospital, Toronto, ON, Canada; 2Department of Anesthesiology, Pain and Perioperative Medicine, Stanford University, Stanford, CA, USA; 3Department of Anesthesiology and Pain Medicine,...
Frontiers in Psychiatry
May 23, 2022
Raquel Bennett, Christian Yavorsky, Gary Bravo
12 citations
Bipolar disorder (type 1) is a serious and chronic psychiatric illness that can be difficult to treat. Many bipolar patients have refractory depressive episodes. Racemic ketamine, a glutamate modulator with prominent dissociate and psychedelic properties, has been demonstrated to have rapid acting antidepressant and anti-obsessional effects which may be useful for treating the symptoms of...
Journal of Eating Disorders
May 6, 2022
Reid Robison, Adele Lafrance, Madeline Brendle et al.
Depression and anxiety outcome measures, safety/tolerability, patient satisfaction, and ease of implementation of group-based ketamine-assisted psychotherapy (G-KAP) delivered to patients in intensive residential eating disorder (ED) treatment were assessed. This study reports on five participants with a diagnosis of an ED and comorbid mood and anxiety disorders who received weekly...
Case Reports in Psychiatry
April 26, 2022
Jeremy Weleff, Kelly A. Bryant, Alexsandra Kovacevich et al.
5 citations
Background. Clinical trials have demonstrated that subanesthetic intravenous ketamine exerts antidepressant effects lasting a week or longer postinfusion, as well as antisuicidal effects starting approximately 4 hours postinfusion and lasting 72 hours or longer. These findings have generated considerable enthusiasm within psychiatry. However, reports of treatment-emergent suicide attempts and...
Frontiers in Behavioral Neuroscience
April 14, 2022
Shuai Yang, Ke Xu, Xuan Xu et al.
This study aims to explore the regulatory effect of S-ketamine on the mechanical allodynia, anxiety-like behaviors and microglia activation in adult male rats exposed to an animal model of post-traumatic stress disorder (PTSD). The rat PTSD model was established by the exposure to single-prolonged stress (SPS), and 1 day later, rats were intraperitoneally injected with 5 mg/kg S-ketamine or...
Physiology and Behavior
January 18, 2022
Paula Michelotti, Francini Franscescon, T. E. Müller et al.
Ketamine is a dissociative anesthetic in human and veterinary clinic, as well as an abuse drug that acts on several neurotransmitter systems. The use of alternative animal models, such as zebrafish, is emerging to study the effects of drugs on neurobehavioral responses. Here, we evaluated the effects of ketamine on memory consolidation (acute protocol), as well as on anxiety-, aggressive-like...
Frontiers in Psychiatry
2022
Joshua Willms, Ben McCauley, Lindsay Kerr et al.
Suicide is the most common cause of death in male resident physicians and the second most common cause of death in resident physicians overall. Physicians also experience high rates of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), and burnout. These conditions frequently develop during medical school, and threaten not only physicians but the patients they care for. A...
Oxidative Medicine and Cellular Longevity
2022
Shiryn D. Sukhram, Grozdena Yilmaz, Jianying Gu
26 citations
Background . Major depressive disorder (MDD) and treatment‐resistant depression (TRD) represent a global source of societal and health burden. To advise proper management of inflammation‐related depression among TRD patients, it is important to identify therapeutic clinical treatments. A key factor is related to proinflammatory cytokines such as interleukin‐ (IL‐) 1 β , IL‐6, and tumor necrosis...
2022
Nicole Amavisca, Nicole Amavisca
1 citation
Given the number of people who are treated for depression each year and the knowledge that treatments work differently for everyone, there is a pressing need to provide a variety of treatment options. Although psychedelic research had been halted for a few decades due to recreational abuse, there has been revived interest due to its therapeutic potential in the treatment of mood disorders and...
Psychiatriki
December 20, 2021
Grigorios N. Karakatsoulis, Eva-Maria Tsapakis, Konstantinos Ν. Fountoulakis
1 citation
Treatment-Resistant Depression (TRD) calls for the development of effective interventions for mood elevation and stabilization. Recently, both ketamine and its S-enantiomer (esketamine) have been investigated with successful clinical trials demonstrating effectiveness in TRD. More specifically, in 2019, intranasally administered esketamine, as opposed to the more effective intravenous ketamine,...